[TENAGA] QoQ TTM Result on 28-Feb-2014 [#2]

Announcement Date
24-Apr-2014
Admission Sponsor
-
Sponsor
-
Financial Year
31-Aug-2014
Quarter
28-Feb-2014 [#2]
Profit Trend
QoQ- 8.15%
YoY- 38.69%
View:
Show?
TTM Result
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
Revenue 44,247,100 42,792,400 40,571,900 38,719,500 37,573,000 37,131,400 36,963,300 12.72%
PBT 8,118,900 7,114,700 5,033,400 5,220,000 5,506,800 5,892,800 7,020,700 10.16%
Tax -1,073,500 -687,900 988,300 919,300 160,700 -542,300 -1,519,900 -20.67%
NP 7,045,400 6,426,800 6,021,700 6,139,300 5,667,500 5,350,500 5,500,800 17.92%
-
NP to SH 7,068,600 6,467,000 6,039,000 6,131,500 5,669,700 5,334,900 5,468,000 18.65%
-
Tax Rate 13.22% 9.67% -19.63% -17.61% -2.92% 9.20% 21.65% -
Total Cost 37,201,700 36,365,600 34,550,200 32,580,200 31,905,500 31,780,900 31,462,500 11.80%
-
Net Worth 45,604,398 43,216,136 33,860,112 33,864,819 36,848,281 33,411,167 34,930,320 19.43%
Dividend
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
Div 1,636,494 1,636,494 1,399,692 1,399,692 1,386,927 1,386,927 1,371,523 12.48%
Div Payout % 23.15% 25.31% 23.18% 22.83% 24.46% 26.00% 25.08% -
Equity
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
Net Worth 45,604,398 43,216,136 33,860,112 33,864,819 36,848,281 33,411,167 34,930,320 19.43%
NOSH 5,644,108 5,642,530 5,643,352 5,644,136 5,643,786 5,568,527 5,537,463 1.27%
Ratio Analysis
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
NP Margin 15.92% 15.02% 14.84% 15.86% 15.08% 14.41% 14.88% -
ROE 15.50% 14.96% 17.84% 18.11% 15.39% 15.97% 15.65% -
Per Share
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
RPS 783.95 758.39 718.93 686.01 665.74 666.81 667.51 11.30%
EPS 125.24 114.61 107.01 108.63 100.46 95.80 98.75 17.14%
DPS 29.00 29.00 25.00 25.00 24.57 25.00 25.00 10.39%
NAPS 8.08 7.659 6.00 6.00 6.529 6.00 6.308 17.92%
Adjusted Per Share Value based on latest NOSH - 5,644,136
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
RPS 763.29 738.19 699.89 667.93 648.15 640.54 637.64 12.72%
EPS 121.94 111.56 104.18 105.77 97.81 92.03 94.33 18.64%
DPS 28.23 28.23 24.15 24.15 23.93 23.93 23.66 12.48%
NAPS 7.867 7.455 5.841 5.8419 6.3565 5.7636 6.0257 19.43%
Price Multiplier on Financial Quarter End Date
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
Date 28/11/14 29/08/14 30/05/14 28/02/14 29/11/13 30/08/13 31/05/13 -
Price 14.26 12.38 12.06 12.00 9.86 8.73 8.35 -
P/RPS 1.82 1.63 1.68 1.75 1.48 1.31 1.25 28.43%
P/EPS 11.39 10.80 11.27 11.05 9.81 9.11 8.46 21.90%
EY 8.78 9.26 8.87 9.05 10.19 10.97 11.83 -18.01%
DY 2.03 2.34 2.07 2.08 2.49 2.86 2.99 -22.73%
P/NAPS 1.76 1.62 2.01 2.00 1.51 1.45 1.32 21.12%
Price Multiplier on Announcement Date
30/11/14 31/08/14 31/05/14 28/02/14 30/11/13 31/08/13 31/05/13 CAGR
Date 22/01/15 31/10/14 16/07/14 24/04/14 23/01/14 31/10/13 18/07/13 -
Price 14.52 13.36 12.46 11.94 11.50 9.43 9.01 -
P/RPS 1.85 1.76 1.73 1.74 1.73 1.41 1.35 23.35%
P/EPS 11.59 11.66 11.64 10.99 11.45 9.84 9.12 17.30%
EY 8.63 8.58 8.59 9.10 8.74 10.16 10.96 -14.71%
DY 2.00 2.17 2.01 2.09 2.14 2.65 2.77 -19.50%
P/NAPS 1.80 1.74 2.08 1.99 1.76 1.57 1.43 16.56%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment